NEW YORK (GenomeWeb News) – Lumera subsidiary Plexera Bioscience said today that it has struck an agreement with MitoSciences to develop an antibody array based on Plexera’s ProteomicProcessor biosensor technology and MitoSciences’ antibodies.
Plexera said the development agreement is “in conjunction with” a previous agreement under which parent firm Lumera partnered with the Medical University of South Carolina to develop a protein-expression profiling assay.
The array will measure changes in mitochondrial proteins, which “are known to be markers for certain pathologies and many adverse drug effects,” said Craig Beeson, associate professor of pharmaceutical sciences at MUSC and the principal investigator on the project.
Plexera COO Tim Londergan said the co-developed array “has the potential to become a mainstream assay” in pharmacokinetics, pharmacology, and toxicology “as pharmaceutical companies desperately need to find new ways to screen and eliminate problematic compounds sooner in the process."
Plexera said the US ADME/Tox market is growing at a compound annual growth rate of 17.2 percent and is expected to reach $2.8 billion in 2009.
Financial terms of the development agreement were not released.